Health Care · Surgical & Medical Instruments & Apparatus

MDXG MIMEDX GROUP, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1376339105 filings
Russell 2000

MDXG at a glance

MIMEDX GROUP, INC. (MDXG, SEC CIK 1376339) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as July 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MIMEDX GROUP, INC. (MDXG) reported revenue of $418.6 million (up 20.0% from FY2024) and net income of $48.6 million. Diluted EPS was $0.32.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding MIMEDX GROUP, INC. (MDXG) shares worth $185.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$418.6M
+20.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
31 funds
$185.1M · +0 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: FTC Second Request received October 15, 2026, potentially extending HSR waiting period 30 days after substantial compliance
  • New transaction risk: Sanara acquisition could face FTC-imposed conditions, restrictions, or prevention, reducing anticipated benefits
  • New financing risk: Hayfin Term Loan availability depends on commitment conditions, with alternative financing potentially costlier
  • New leverage risk: Expected Hayfin Term Loan may increase debt service and restrict additional borrowing, investments, dividends, and asset sales
  • New operational risk: Acquisition-related review and integration could divert management resources and disrupt employees, customers, and business relationships

Management Discussion & Analysis

  • Revenue $62.3M, down 45.2% YoY from $113.7M
  • Gross margin 79.8% vs 83.5% YoY, pressured by Wound pricing and unfavorable mix
  • Best segment Surgical revenue $40.0M, up 9.1%; worst Wound revenue $22.3M, down 71.0%
  • Net cash $120.8M, up $2M sequentially; operating cash used $4.2M through nine months
  • Near-term headwinds: Medicare reimbursement changes and FTC Second Request delaying Sanara acquisition clearance

AI summary of the MDXG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item EX-99.3: Item EX-99.3

  • Proposed Sanara acquisition values target at approximately $350 million, funded partly by a $300 million term loan and 4.4 million MDXG shares
  • Debt terms: six-year maturity at SOFR plus 6.25%, creating meaningful post-close interest and leverage exposure

Item EX-99.1: Item EX-99.1

  • Q3 net sales $62.3M, down 45%, driven by Wound sales falling 71% despite Surgical sales growth of 9%
  • Adjusted EBITDA $2.1M, margin 3.3%, versus $35.0M and 30.7% prior year, showing severe earnings pressure

Item EX-99.2: Item EX-99.2

  • Q3 net sales $62MM, with Surgical $40MM and Wound $22MM
  • Surgical volume growth reached mid-teens, while Wound Care Center volumes rose 7% sequentially and over 20% year-over-year

Item 2.02: Results of Operations and Financial Condition

  • MiMedx announced second-quarter 2026 results on October 28, 2026
  • Detailed financial results and management commentary are provided in Exhibit 99.1, the earnings press release

Item 7.01: Regulation FD Disclosure

  • October 28, 2026 earnings call covering third-quarter 2026 financial and operating results
  • Investor presentation updated October 28, 2026, offering supplemental operating and strategic information
Filed Oct 16, 2026Full analysis →

Item 8.01: Other Events

  • FTC issued a Second Request on October 15, 2026, extending the HSR antitrust waiting period
  • Merger closing delayed until 30 days after substantial compliance, unless FTC terminates or parties extend the period
Filed Aug 11, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • MiMedx announced entry into a merger agreement on July 29, 2026, with Sanara MedTech
  • Investor presentation expected to outline transaction timing, synergies, combined surgical revenue and Adjusted EBITDA margin

Item 1.01: Entry into a Material Definitive Agreement

  • MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration
  • $300.0 million first-lien senior secured term loan planned, increasing leverage and replacing MiMedx’s existing credit facility

AI summaries of MDXG 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MDXG

Don't miss the next MDXG filing

  • Alerts as it files. A push when MDXG files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MDXG, by share count.
  • Ask anything. An AI agent that reads every MDXG filing and answers with sources.

MDXG alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DOUG RICEFJul 2, 2026$3.95
Maersk-Moller KimberlyFJun 24, 2026$3.83
PUHY DOROTHY EAJun 10, 2026$3.64
HAWKINS WILLIAM AAJun 10, 2026$3.64
Olson TiffanyAJun 10, 2026$3.64
BIERMAN JAMES LAJun 10, 2026$3.64
Newton ToddAJun 10, 2026$3.64
Maersk-Moller KimberlyFMar 13, 2026$4.38

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$348.9M$418.6M
Gross Profit-$288.8M$345.6M
Operating Income$37.1M$58.9M$63.9M
Net Income$58.2M$42.4M$48.6M
Gross Margin-82.8%82.6%
Op. Margin-16.9%15.3%
Net Margin-12.2%11.6%
Balance Sheet
Total Assets$239.0M$263.9M$342.7M
Equity-$193.1M$256.5M
ROE-22.0%18.9%
Per Share
EPS-$0.28$0.32
Cash Flow
Operating CF-$66.2M$74.0M
CapEx$2.0M--

Source: XBRL data in MIMEDX GROUP, INC. (MDXG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MDXG share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MDXG shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$185.1M
Q2 202631$154.5M
Q1 202630$146.2M
Q4 202528$238.8M
Q3 202530$253.7M
Q2 202530$221.8M
Q1 202529$177.0M
Q4 202424$178.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MDXG filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 28, 2026Analysis
8-KOct 28, 2026Analysis-
8-KOct 16, 2026Analysis-
8-KAug 11, 2026Analysis-
8-KJul 29, 2026Analysis-
8-KJul 29, 2026Analysis-
10-QJul 29, 2026Analysis
4Jul 7, 2026--
4Jun 25, 2026--
8-KJun 16, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
10-QApr 29, 2026Analysis
8-KApr 29, 2026Analysis-
8-KApr 16, 2026Analysis-
4Mar 17, 2026--
4Mar 17, 2026--
4Mar 12, 2026--
4Mar 12, 2026--
4Mar 12, 2026--
4Mar 6, 2026--
4Mar 6, 2026--

Related Health Care companies

All Health Care →

MDXG SEC filings: frequently asked questions

Which institutions hold MDXG stock?

As of September 30, 2026, the largest MIMEDX GROUP, INC. (MDXG) holders among the 13F filers tracked by SignalX were BlackRock ($60.6 million), Vanguard Capital Management LLC ($24.0 million), State Street Corp ($20.5 million), Renaissance Technologies LLC ($11.0 million), AQR Capital Management ($10.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MDXG's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MIMEDX GROUP, INC. (MDXG) reported revenue of $418.6 million (up 20.0% from FY2024) and net income of $48.6 million. Diluted EPS was $0.32. The figures come from the XBRL data in the 10-K.

What did MDXG report in its latest 8-K?

MIMEDX GROUP, INC. (MDXG) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Proposed Sanara acquisition values target at approximately $350 million, funded partly by a $300 million term loan and 4.4 million MDXG shares.

What are the latest MDXG SEC filings?

MIMEDX GROUP, INC. (MDXG) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on July 7, 2026.

What is MDXG's SEC CIK number?

MIMEDX GROUP, INC. (MDXG)'s SEC Central Index Key (CIK) is 1376339. EDGAR lists every MDXG filing under that number.

Ask anything about MDXG

The research agent reads MDXG's filings, financials, insider trades and 13F holders, then answers with sources.